We showed that EP4 antagonists at nontoxic doses exerted strong anti-tumor, anti-metastatic and SLC-reductive effects in a COX-2 expressing, highly metastatic, syngeneic murine breast cancer model22. Here, PTGER4 is linked to neoplasm.